Atrogi is developing novel compounds and treatments of metabolic disorders and a robust patent portfolio has been generated to develop the commercial asset and increase value. Several patents have already been granted; here are two of the more recent from June and August.
US 11,357,757
Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycemia
US 11,427,539
Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycemia
